Clinical application of immunogenic cell death inducers in cancer immunotherapy: turning cold tumors hot

Frontiers in Cell and Developmental Biology, Journal Year: 2024, Volume and Issue: 12

Published: May 7, 2024

Immunotherapy has emerged as a promising cancer treatment option in recent years. In immune “hot” tumors, characterized by abundant cell infiltration, immunotherapy can improve patients’ prognosis activating the function of cells. By contrast, “cold” tumors are often less sensitive to owing low immunogenicity tumor cells, an inhibitory microenvironment, and series immune-escape mechanisms. Immunogenic death (ICD) is cellular process facilitate transformation eliciting innate adaptive responses through release (or exposure to) damage-related molecular patterns. Accumulating evidence suggests that various traditional therapies induce ICD, including chemotherapy, targeted therapy, radiotherapy, photodynamic therapy. this review, we summarize biological mechanisms hallmarks ICD introduce some newly discovered technologically innovative inducers activate system at level. Furthermore, also discuss clinical applications combing with immunotherapy. This review will provide valuable insights into future development ICD-related combination therapeutics potential management for tumors.

Language: Английский

---

Mitochondria targeted biomimetic platform for chemo/photodynamic combination therapy against osteosarcoma

International Journal of Pharmaceutics, Journal Year: 2024, Volume and Issue: 652, P. 123865 - 123865

Published: Jan. 28, 2024

Language: Английский

---

Advancements in Stimulus-Responsive Co-Delivery Nanocarriers for Enhanced Cancer Immunotherapy

International Journal of Nanomedicine, Journal Year: 2024, Volume and Issue: Volume 19, P. 3387 - 3404

Published: April 1, 2024

Abstract: Cancer immunotherapy has emerged as a novel therapeutic approach against tumors, with immune checkpoint inhibitors (ICIs) making significant clinical practice. The traditional ICIs, PD-1 and PD-L1, augment the cytotoxic function of T cells through inhibition tumor evasion pathways, ultimately leading to initiation an antitumor response. However, implementation ICIs encounters obstacles stemming from existence immunosuppressive microenvironment inadequate infiltration CD8 + cells. Considerable attention been directed towards advancing immunogenic cell death (ICD) potential solution counteract microenvironment. This holds promise in transforming "cold" tumors into "hot" that exhibit responsiveness antitumor. By combining ICD synergistic response can be achieved. combination inducers PD-1/PD-L1 is hindered by issues such poor targeting uncontrolled drug release. An advantageous presented stimulus-responsive nanocarrier integrating physicochemical properties inhibitors, facilitating precise delivery specific tissues for optimal therapy. Moreover, these nanocarriers leverage distinct features accomplish controlled release regulate kinetics delivery. article aims investigate advancement co-delivery utilizing inhibitors. Special focus dedicated exploring advantages recent advancements this system enabling inducers. molecular mechanisms are concisely summarized. In conclusion, we examine research prospects challenges could greatly enhance immunotherapeutic approaches cancer treatment. Keywords: therapy, death, co-delivery, immune-checkpoint

Language: Английский

---

Preparation of pH-Sensitive Astragalus Polysaccharide Nanoparticles Loaded with Paclitaxel and Evaluation of Antitumor Activity

Journal of Pharmaceutical Innovation, Journal Year: 2025, Volume and Issue: 20(1)

Published: Jan. 23, 2025

Language: Английский

---